ABSTRACT Background: Systemic lupus erythematosus (SLE) is the prototypic multisystem autoimmune disorder with a wide range of clinical presentations impacting almost all organs and tissues, such extreme heterogeneity suggests that SLE represents a syndrome rather than a single disease. Although the precise etiologic mechanism is unknown, genetic, hormonal, and environmental factors, as well as immune abnormalities, have been detected. Associations between lupus onset and age, sex, geography, and race have also been established. Aim of the work: This review will focus on advances in the diagnosis and management of SLE.
INTRODUCTION
Systemic lupus erythematosus (SLE) is a multisystem autoimmune rheumatic disease with a highly variable course.It is most prevalent in females of childbearing age with a female: male ratio of 9:1 in this population. The prevalence of SLE is also higher in certain ethnicities, reflected in prevalence rates of 40/100 000 persons in Northern European cohorts in comparison with rates of 200/100 000 persons in studies of patients of African-American descent 1 . Patients with SLE may present with various systemic manifestations including diverse abnormalities of the skin, kidney, and haematological, pulmonary, and reproductive and musculoskeletal systems. The general symptoms are not specific. Common manifestations may include arthralgias and arthritis, malar and other skin rashes, pleuritis or pericarditis, renal or CNS involvement, hematologic cytopenias and weight changes are the most common symptoms in new cases or recurrent active SLE flares. Fatigue, the most common constitutional symptom associated with SLE, can be due to active SLE, medications, lifestyle habits, or concomitant fibromyalgia or affective disorders. Fatigue due to active SLE generally occurs in concert with other clinical and laboratory markers. Fever, another common yet nonspecific symptom of SLE, may also result from many causes, the most common of which include active SLE, infection, and drug fever 2 . Careful history taking may help to differentiate these. Weight loss may occur in patients with active SLE. Weight gain may also be due to corticosteroid treatment or active disease such as nephrotic syndrome anasarca 3 . These symptoms can mimic other autoimmune diseases, infectious diseases, endocrine abnormalities, chronic fatigue, and fibromyalgia 4 . SLE significantly increases the risk of cardiovascular disease as well.
SLE a chronic, recurrent, potentially multisystem inflammatory which can be fatal and difficult to diagnose 5 . The disease has no single diagnostic marker; instead, it is identified through a combination of clinical and laboratory criteria 6 . Accurate diagnosis of systemic lupus erythematosus is important because treatment can reduce morbidity 7 and mortality,12 particularly from lupus nephritis. This article reviews evidence-based recommendations for the diagnosis of systemic lupus erythematosus by primary care physicians. The 1992 Revised 673 American College of Rheumatology (ACR) Classification Criteria however offers developed to aid trial design, offer a useful aide-mémoire to the rheumatologist of some of the more common features of SLE. Management is complex and involves clinicians across many different specialties, with important variations in practice apparent across and within these specialties. For example, prescription of antimalarial drugs and testing for antiphospholipid antibodies are routine among rheumatologists but not among nonrheumatologists 8 . Prescribed doses for glucocorticoid regimens also differ across specialties 9 . SLE is one of a small number of truly multisystem disorders. The heterogeneous nature of the disease can result in delayed diagnosis and cause considerable difficulty in the design of robust clinical trials. There is no diagnostic test specific for SLE and as such the diagnosis remains a clinical one, relying on a combination of clinical and laboratory features. The 1992 Revised American College of Rheumatology (ACR) Classification Criteria, while developed to aid trial design, offer a useful aide-mémoire to the rheumatologist of some of the more common features of SLE 10 .
DIAGNOSIS OF SYSTEMATIC LUPUS ERYTHEMATOSUS (SLE)
The diagnosis of SLE is mainly done through: (11, 16, 17) . 18 . Depending on the stage of disease, deformities may be present on radiograph.  Renal ultrasonography to assess kidney size and to rule out urinary tract obstruction when there is evidence of renal impairment.  Chest radiography (eg, for suspected pleural effusion, interstitial lung disease, cardiomegaly).  Echocardiography (eg, for suspected pericardial involvement, to assess for a source of emboli, or noninvasive estimation of pulmonary artery pressure; and for evaluation of suspected valvular lesions, such as verrucae).  Computed tomography (CT) (eg, for abdominal pain, suspected pancreatitis, interstitial lung disease).  Magnetic resonance imaging (MRI) (eg, for focal neurologic deficits or cognitive dysfunction).
3-Diagnostic testing
b. Biopsy of an involved organ (eg, skin or kidney) is necessary in some cases. Typical histologic findings in various organs in SLE are discussed in topic reviews devoted to the particular sites of involvement. c. Electrocardiography in the assessment of chest pain that may be due to pericarditis or to myocardial ischemia. d. Tests to assess for pulmonary embolism in a patient with pleuritic chest pain and dyspnea e. Diffusing capacity for carbon monoxide (DLCO) to assess for suspected pulmonary hemorrhage and to estimate the severity of interstitial lung disease.
MANGEMENT OF SYSTEMATIC LUPUS ERYTHEMATOSUS (SLE)
The approach to the treatment of signs and symptoms of lupus depends on the type and the severity of disease. General recommendations for all patients include sun protection, proper diet and nutrition, exercise, smoking cessation, appropriate immunizations, and management of comorbid conditions.
A. Pharmacotherapy

ANA Testing
Titer<1.4
Explanation found SLE ruled out
No explanation
Refer Table  1 ), corticosteroids should be used at the lowest possible dose and only for periods necessary to control an active exacerbation of lupus. 19, 20 3. Immunosuppressants :are primarily used in more severe cases of lupus when high-dose corticosteroids or antimalarial treatments have failed to control the signs and symptoms of disease. They are also used when it is necessary to induce and maintain remission and to reduce flares or relapses. Immunosuppressants may be given with high-dose corticosteroids to control flares, to achieve a lower dose of each medication, or to reduce the occurrence of adverse events. The most commonly used agents in this class are cyclophosphamide (Cytoxan, Bristol-Myers Squibb) and azathioprine (Azasan, Salix; Imuran, GlaxoSmithKline). Mycophenolate (CellCept, Genentech/Roche) has also been used for lupusrelated kidney problems. Side effects of this drug class are listed in (Table 1) . 19, 20 4. Antimalarial Medication: Some antimalarial agents have proved effective in treating the various signs and symptoms of lupus and preventing subsequent flares. Although the exact mechanism is unclear (see Table 1 ), antimalarials may interfere with T-cell activation and inhibit cytokine activity. These agents may also inhibit intra-cellular toll-like receptors, which recognize and bind foreign materials, thereby contributing to activation of the immune system 21 . Hydroxychloroquine (e.g., Plaquenil, Sanofi) is the most commonly studied and used drug in its class, but it has the potential to cause serious visual and muscle disturbances.
Monoclonal Antibodies  "Belimumab"
In March 2011, the FDA approved the first human monoclonal antibody for the treatment of lupus. Belimumab (Benlysta, Human Genome Sciences/GlaxoSmithKline) is the first agent in more than 50 years to be approved for patients with lupus. Belimumab inhibits the activation of B lymphocytes by interfering with a protein necessary for B-cell activity (BLyS). Previously known as LymphoStat-B, belimumab is recommended for patients with active SLE who are receiving standard therapy with NSAIDs, antimalarials, corticosteroids, and/or immunosuppressants. Common adverse effects are presented in Table 1 22 .
 Rituximab
As a genetically engineered chimeric monoclonal antibody directed against the CD20 antigen, rituximab (Rituxan, Genentech/Roche) has also shown potential in the treatment of SLE. It is believed that B cells responsible for the production of pathogenic autoantibodies, and other immune-mediated substances associated with lupus, are depleted by rituximab. During the past few years, a number of open-label and retrospective studies have reported promising results with rituximab (when taken with corticosteroids and other immunosuppressants in the management of both pediatric-onset and adultonset lupus).
Benefits of rituximab have also been noted in patients with lupus nephritis, arthralgia, arthritis, serositis, cutaneous vasculitis, mucositis, rashes, fatigue, and neurological and refractory symptoms. Adverse events were generally mild. Mild-to-moderate infusion reactions were reported most often. 23, 24 Some randomized controlled studies have provided mixed results regarding the efficacy and role of rituximab in the treatment of SLE. In a study by Terrier et al., clinical responses were reported in 71% of patients who received rituximab, demonstrating a significant benefit in refractory lupus (with or without concomitant immunosuppressive therapy). Cutaneous, articular, renal, and hematological improvements were noted most often, along with an acceptable tolerance profile. 25 A systematic review covering 188 SLE patients treated with various regimens of rituximab, 91% showed a significant improvement in one or more systemic manifestations, particularly in patients with renal involvement (e.g., lupus nephritis). Adverse events were experienced by 23% of patients, and infections were reported most often 26 .However, two additional randomized, placebo-controlled studies, conducted since 2010, failed to demonstrate significant clinical improvements with rituximab in patients receiving concomitant steroid therapy 27 . Despite the favorable tolerability and safety profile of rituximab, further evaluation of this drug is required for patients with SLE. Methylprednisolon e IV 500-1,000 mg daily for 3 to 6 days (acute flare) 
Immunosuppressants
B. Additional Treatment Options
Researchers have been particularly interested in the use of stem-cell transplantation to introduce healthy cells into the body in order to help rebuild the immune system. Both DHEA and rituximab have been studied in clinical trials and have provided improvements in patients' quality of life. DHEA is believed to help in the regulation of sex hormones, whereas rituximab decreases the number of B cells and may be most beneficial in patients who do not respond to the other traditionally used immunusuppressants 24, 25 .
C. Patient Education
Stress the importance of adherence to medications and follow-up appointments for detection and control of SLE disease. Instruct patients with SLE to seek medical care for evaluation of new symptoms, including fever. Advise them regarding their heightened risks for infection and cardiovascular disease. Educate patients with SLE regarding aggressive lipid and blood pressure goals to minimize the risk of coronary artery disease. Instruct patients with SLE to avoid exposure to sunlight and ultraviolet light. Also, encourage them to receive nonlive vaccines during stable periods of disease, to quit smoking, and to carefully plan pregnancies.
PREGNANCY
Women with SLE are at increased risk for serious medical and pregnancy complications, such as thrombosis, infection, thrombocytopenia, transfusion, pre-eclampsia, and death28. Because of the high risk of miscarriage, stillbirths, premature delivery, and exacerbation of SLE, it is recommended that women not become pregnant if they have active disease or significant organ involvement. Oral contraceptives must be given cautiously because high doses of estrogen can cause SLE exacerbations 28 .Pregnancy outcomes are improved if conception is delayed until SLE has been inactive for at least 6 months and if the patient's medications are adjusted in advance. Baseline and monthly monitoring (e.g., laboratory tests, ultrasonography, fetal surveillance tests, maternal echocardiography, and antibody testing) should be performed for all pregnant lupus patients, because signs and symptoms of lupus flares may be similar to those typical of pregnancy 28 . Neonates should be carefully evaluated for placental transfer of maternal antibodies, which could lead to cutaneous or cardiac complications (e.g., congenital heart block and cardiomyopathy). If a woman is pregnant and has active SLE, corticosteroids may be prescribed with caution to manage the disease. Most steroids are Pregnancy Category C drugs. NSAIDs (Pregnancy Category C and D) have also been used, but to a lesser extent, and they should be avoided during early pregnancy and the last trimester. If necessary, hydroxychloroquine may be used, but it is also a Pregnancy Category C drug. Therefore, therapy must be individualized and the drug's benefits and risks must be carefully considered. Immunosuppressive agents are contraindicated in pregnancy, except for azathioprine, a Pregnancy Category C drug. In women with SLE and antiphospholipid antibodies, prophylaxis with aspirin, lowmolecular-weight heparin, or both, is indicated for the prevention of fetal loss 28 .
CONCLUSION
Although no cure has been discovered for this autoimmune disease, many medications are available to help control flares, to maintain remission, and to manage symptoms. Pharmacists and other health care professionals can play a vital role in treatment by educating patients, monitoring their therapeutic regimens, and identifying preventable drug-associated adverse events. Current research is under way, with the hope that improved quality of life and increased survival can be achieved for the many patients affected by SLE each year.
